Haemonetics Corporation
HAE
$57.17
$0.280.49%
NYSE
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 348.54M | 345.51M | 336.17M | 343.29M | 336.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 348.54M | 345.51M | 336.17M | 343.29M | 336.25M |
| Cost of Revenue | 148.63M | 154.31M | 151.64M | 154.35M | 151.32M |
| Gross Profit | 199.92M | 191.20M | 184.53M | 188.94M | 184.93M |
| SG&A Expenses | 105.74M | 104.72M | 91.58M | 111.09M | 106.11M |
| Depreciation & Amortization | 12.23M | 12.26M | 12.47M | 10.43M | 6.91M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 282.43M | 287.82M | 270.14M | 289.86M | 277.26M |
| Operating Income | 66.11M | 57.69M | 66.03M | 53.44M | 58.99M |
| Income Before Tax | 49.92M | 44.70M | 46.71M | 23.41M | 44.03M |
| Income Tax Expenses | 12.42M | 10.87M | 8.34M | 3.05M | 12.79M |
| Earnings from Continuing Operations | 37.49M | 33.83M | 38.37M | 20.37M | 31.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.49M | 33.83M | 38.37M | 20.37M | 31.24M |
| EBIT | 66.11M | 57.69M | 66.03M | 53.44M | 58.99M |
| EBITDA | 95.14M | 86.91M | 95.17M | 72.47M | 82.52M |
| EPS Basic | 0.75 | 0.66 | 0.75 | 0.40 | 0.62 |
| Normalized Basic EPS | 0.71 | 0.62 | 0.90 | 0.58 | 0.70 |
| EPS Diluted | 0.74 | 0.66 | 0.74 | 0.40 | 0.61 |
| Normalized Diluted EPS | 0.70 | 0.62 | 0.88 | 0.57 | 0.69 |
| Average Basic Shares Outstanding | 50.29M | 50.90M | 50.94M | 50.79M | 50.77M |
| Average Diluted Shares Outstanding | 50.64M | 51.24M | 51.56M | 51.41M | 51.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |